Abstract
Marine organisms are the excellent sources for biologically active compounds. Cnidarian venoms are potentially valuable materials used for biomedical research and drug development. The present work was carried out to analyse haemolytic, analgesic and CNS depressant activity of sea anemone Heteractis aurora. In haemolytic assay, among the five different RBC blood cells, the chicken blood exhibited maximum hemolytic activity of 64 Hemolytic Unit (HU). The maximum Analgesic Ratio (AR) of 5 recorded at 15 and 30 min interval and minimum was recorded after 45, 60 and 120 min time intervals. In jumping response activity, the maximum of 5 AR recorded at 15, 30 & 45 min and minimum was recorded at 90 & 120 min time intervals. The maximum decrease of depressant activity of 45.07% was determined in CNS depressant activity. Anti-inflammatory activity showed significant inhibition by crude extract of Heteractis aurora.
Keywords: Analgesic activity, CNS depressant activity, Heteractis aurora, Haemolytic activity, Sea anemone.
Central Nervous System Agents in Medicinal Chemistry
Title:Analgesic and CNS Depressant Activities of Sea Anemone Heteractis aurora Nematocyst Toxin
Volume: 16 Issue: 3
Author(s): Sengapillai Thangaraj, Subramanian Bragadeeswaran, Natarajah Srikumaran and Anbukkarasu Suguna
Affiliation:
Keywords: Analgesic activity, CNS depressant activity, Heteractis aurora, Haemolytic activity, Sea anemone.
Abstract: Marine organisms are the excellent sources for biologically active compounds. Cnidarian venoms are potentially valuable materials used for biomedical research and drug development. The present work was carried out to analyse haemolytic, analgesic and CNS depressant activity of sea anemone Heteractis aurora. In haemolytic assay, among the five different RBC blood cells, the chicken blood exhibited maximum hemolytic activity of 64 Hemolytic Unit (HU). The maximum Analgesic Ratio (AR) of 5 recorded at 15 and 30 min interval and minimum was recorded after 45, 60 and 120 min time intervals. In jumping response activity, the maximum of 5 AR recorded at 15, 30 & 45 min and minimum was recorded at 90 & 120 min time intervals. The maximum decrease of depressant activity of 45.07% was determined in CNS depressant activity. Anti-inflammatory activity showed significant inhibition by crude extract of Heteractis aurora.
Export Options
About this article
Cite this article as:
Thangaraj Sengapillai, Bragadeeswaran Subramanian, Srikumaran Natarajah and Suguna Anbukkarasu, Analgesic and CNS Depressant Activities of Sea Anemone Heteractis aurora Nematocyst Toxin, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1871524916666160129101049
DOI https://dx.doi.org/10.2174/1871524916666160129101049 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Intervertebral Disc and Nucleus Replacement Devices and Instrumentations
Recent Patents on Biomedical Engineering (Discontinued) Polyglandular Autoimmune Syndromes
Current Immunology Reviews (Discontinued) Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Endocannabinoids: A New Family of Lipid Mediators Involved in the Regulation of Neural Cell Development
Current Pharmaceutical Design Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Anxiety and Depression in Obstructive Sleep Apnea: Prevalence and Gender/Ethnic Variance
Current Respiratory Medicine Reviews Antipsychotic Medication Adherence and Satisfaction Among Palestinian People with Schizophrenia
Current Clinical Pharmacology NMDA Receptors are not Alone: Dynamic Regulation of NMDA Receptor Structure and Function by Neuregulins and Transient Cholesterol-Rich Membrane Domains Leads to Disease-Specific Nuances of Glutamate- Signalling
Current Topics in Medicinal Chemistry Transplantation of Adipose Tissue-Derived Stem Cells for Treatment of Focal Cerebral Ischemia
Current Neurovascular Research Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands
Current Neuropharmacology Molecular Regulation and Pharmacology of Pacemaker Channels
Current Pharmaceutical Design Zn(L-proline)2: An Efficient and Recyclable Catalytic System for the Asymmetric Multicomponent Synthesis of 2-amino-4H-chromenes in Water Under Controlled Microwave Heating
Current Microwave Chemistry Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery Oral Chemotherapy in Elderly Women with Metastatic Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Neurogenesis as a Therapeutic Strategy for Cognitive Aging and Alzheimers Disease
Current Alzheimer Research